Changes for page Cipla

Last modified by Asif Farooqui on 2021/03/22 18:12
From version < 1.2 >
edited by Asif Farooqui
on 2020/05/04 16:24
To version < 1.3 >
edited by Asif Farooqui
on 2020/05/04 16:24
< >
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -2,10 +2,8 @@
2 2  {{toc/}}
3 3  {{/box}}
4 4  
5 -= Paragraph 1 =
5 += Company Overview =
6 6  
7 -Company Overview
8 -
9 9  Established in 1935, Cipla is a global pharmaceutical company focused on responsible and sustainable growth through deep & wide portfolio and strong customer relationships across its home markets of India, South Africa, US and other key regulated and emerging markets.
10 10  
11 11  The company's strengths in the respiratory, anti-retroviral, urology, cardiology and CNS segments are well-known. The company's 46 manufacturing facilities around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to its 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Mar’19) and 3rd largest in the pharma private market in South Africa (IQVIA MAT Mar’19). For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. The company's paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders
... ... @@ -182,3 +182,5 @@
182 182  
183 183  
184 184  R&D investments stand at INR 308 crores or ~~7% of sales
183 +
184 += References =
This site is funded and maintained by Fintel.io